article thumbnail

A Different Future Was Possible: Reflections on the US Pandemic Response

Bill of Health

A collective policy response complemented this rhetorical and ideological framing. In March 2020 , Congress expanded unemployment benefits at unprecedented levels, subsidized businesses, guaranteed paid sick leave for many workers, and broadened Medicaid eligibility. states had fully banned indoor dining. This one is no different.

COVID-19 354
article thumbnail

Americans Grew Digital Health-Data Muscles in the Pandemic – New Insights from the Pew Charitable Trusts

Health Populi

“Most Americans clearly recognize the potential benefits that improved health IT can offer, and they want this transformation of the health care system to continue,” the Pew Charitable Trusts research concludes in Most Americans Want to Share and Access More Digital Health Data.

COVID-19 118
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What will the next year look like for telehealth? 'Well above pre-pandemic levels'

Healthcare IT News - Telehealth

We expect there will be some ebbs and flows in the overall number of telehealth visits, driven by a combination of ongoing COVID-19 spikes, such as the recent Delta variant, changes in federal policies and waivers for reimbursement, and further integration of telehealth services into care models across service lines.

COVID-19 202
article thumbnail

Single Institutional Review Board Exception Determination Set to Expire May 11, 2023

Hall Render

On February 10, 2023, the Office for Human Research Protections (“OHRP”) announced that the COVID-19 single institutional review board (“IRB”) exception determination will expire on May 11, 2023, consistent with the expiration of the COVID-19 Public Health Emergency (“PHE”).

article thumbnail

Federal Preemption of State Attempts To Ban FDA-Approved Abortion Drugs After Dobbs

Drug & Device Law

In enacting the FDCA, Congress created the FDA and charged it with “promot[ing] the public health by promptly and efficiently reviewing clinical research and taking appropriate action on the marketing of regulated products in a timely manner.” 2020 WL 5189995, at *9-10 (D. 31, 2020) (quoting and following Bartlett ); Javens v.

FDA 116